Press "Enter" to skip to content

Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant

Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities

  • The plant is currently filling vials of COVID-19 vaccines for AstraZeneca plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ).
  • The company plans to install two 2,000-liter single-use bioreactors at the Anagni plant and the infrastructure required for another six 2,000-liter single-use bioreactors. 
  • The initial expansion is expected to be commissioned and operational in April 2023 and will increase the site’s workforce by as many as 100 employees. 
  • Later phases of the planned expansion may include 16,000 liters of total flexible manufacturing capacity, enabling a 2,000-liter to 8,000-liter batch production scale.
  • Price Action: CTLT shares are up 0.28% at $113.00 during the market session on the last check Wednesday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *